From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Test your knowledge on GVHD treatment risks and CRS development

Last Updated: Wednesday, May 17, 2023
Loading...
Advertisement
News & Literature Highlights

Targeted Oncology

Acute GVHD responds quickly to itolizumab treatment in phase 1b trial

Transplantation and Cellular Therapy

Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease

Journal of Clinical Oncology

Naive T-cell depletion to prevent chronic graft-versus-host disease

Blood

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

The ASCO Post

Abatacept for prophylaxis of acute graft-vs-host disease

Translation and Cellular Therapy

A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease

Blood

Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo

Translation and Cellular Therapy

Impact of conditioning regimen and graft-versus-host disease prophylaxis on the outcome of haploidentical peripheral blood stem cell transplantation for high-risk severe aplastic anaemia in children and young adults

Journal of Clinical Oncology

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

2022 ASH Annual Meeting

A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following alloHCT

Advertisement
Advertisement